Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02818023
Recruitment Status : Active, not recruiting
First Posted : June 29, 2016
Last Update Posted : July 14, 2020
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Yana Najjar, University of Pittsburgh

Brief Summary:
The study plans to treat patients with pembrolizumab and thus blocking the PD-1/PD-L1 axis would render tumor-infiltrating lymphocytes (TILs) in the tumor parenchyma more functional as a consequence of BRAF inhibition, such that T cell activation by BRAFi would not be dampened by the PD-1/PD-L1 interaction. This combination would reverse dysfunction among T cells in the tumor parenchyma, maximizing T cell mediated immune anti-tumor efficacy. Progression free survival (PFS) with pembrolizumab in KEYNOTE-001 was 57% at 6 months, and 46.4% in the more recently reported phase III trial. PFS with vemurafenib treatment in BRIM-3 was ~50% at 6 months. Combined treatment with pembrolizumab, cobimetinib and vemurafenib for BRAF mutant melanoma is hypothesized to be safe and to improve the PFS compared to these recent historical controls. Because this combination has not yet been tested, and because the primary objective is to assess safety, the investigators are staging accrual in the first phase of the trial. The study aims to accrue up to 30 patients to the mTPI design of this study with the expectation that there will be at least 30 patients treated at RP2D. In case there are less than 30 patients on the RP2D, additional patients will be accrued. Patients will continue to receive treatment with pembrolizumab, vemurafenib and cobimetinib until disease progression or dose limiting toxicity. Patients with treatment response and no dose limiting toxicity may receive treatment with pembrolizumab for up to 24 months.

Condition or disease Intervention/treatment Phase
Melanoma Drug: Pembrolizumab Drug: Vemurafenib Drug: Cobimetinib Phase 1

Detailed Description:
Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab, vemurafenib and cobimetinib will commence on the same day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Study Start Date : July 2016
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : May 2024


Arm Intervention/treatment
Experimental: Pembrolizumab plus vemurafenib and Cobimetinib
  • Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.
  • One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib.
Drug: Pembrolizumab

Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.

One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib.


Drug: Vemurafenib

Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.

One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib.


Drug: Cobimetinib
Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.




Primary Outcome Measures :
  1. Percentage of participants that experience a dose-limiting toxicity [ Time Frame: Up to 2 years ]
    determine the safety and maximum tolerated dose of vemurafenib and cobimetinib with pembrolizumab


Secondary Outcome Measures :
  1. overall response rate (ORR) [ Time Frame: Up to 2 years ]
  2. progression free survival [ Time Frame: Up to 2 years ]
  3. overall survival [ Time Frame: up to 2 years ]

Other Outcome Measures:
  1. assessment of tumor microenvironment and immune response via biomarker level measurement [ Time Frame: Up to 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide written informed consent obtained prior to the initiation of study procedures.
  2. Male and female subjects who are at least 18 years of age.
  3. Histologically confirmed unresectable stage III or stage IV melanoma (AJCC 7th edition classification). Cutaneous melanoma and mucosal melanoma will be eligible.
  4. Only patients with BRAF V600E or V600K mutated tumors will be enrolled.
  5. Baseline skin exam is required for all patients. Note: Cutaneous squamous cell carcinoma (SCC) lesions identified at baseline must be excised.
  6. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Baseline measurements must be obtained within 4 weeks prior to registration.
  7. Adequate hematologic, renal, and liver function as evidenced by the following (within 4 weeks prior to starting the study drugs):

    • WBC ≥ 3,000/mm3
    • ANC ≥ 1500
    • Hemoglobin ≥ 9g/dL (women) or ≥ 11g/dL (men) Platelets ≥ 100,000/mm3 Serum Creatinine ≤ 1.5 x upper limit of normal (ULN)
    • Serum Bilirubin ≤ 1.5 x ULN
    • Serum AST and ALT ≤ 2.5 x ULN

    Note: (supportive transfusions will be allowed during screening and during treatment as deemed necessary by the treating physician)

  8. EKG documenting QTc interval < 480 msec and no clinically significant arrhythmia
  9. Fully recovered from any effects of major surgery, and be free of significant infection.
  10. ECOG performance status of 0 or 1.
  11. Female patients of child bearing potential must have a negative pregnancy test within 7 days from the time of registration .
  12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  13. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for greater than 1 year.
  14. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
  15. Patients with brain metastases may be enrolled if brain metastases have been treated by surgery and/or radiation and are stable on 2 week repeat scan.

Exclusion Criteria:

  1. Serious clinically significant illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, uncontrolled hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), bleeding disorders, symptomatic autoimmune diseases (such as inflammatory bowel disease, autoimmune hepatitis, uncontrolled hypo or hyperthyroidism), severe obstructive or restrictive pulmonary diseases, retinopathy, active systemic infections, and inflammatory bowel disorders.
  2. Known HIV or AIDS-related illness, or active HBV and HCV.
  3. Has a known history of active TB (Bacillus Tuberculosis)
  4. History of grade 4 immune-related adverse events requiring treatment with prednisone, or grade 3 immune-related adverse events requiring prednisone >10 mg/kg for >12 weeks, if previously treated with ipilimumab.
  5. Prior therapy with anti-PD-1 agent(s) in the metastatic setting. Treatment with anti-PD1 in the adjuvant setting is permitted.
  6. Prior therapy with a BRAF and/or MEK and/or ERK inhibitors in the metastatic setting. Treatment with BRAF/MEKi in the adjuvant setting is permitted.
  7. Refractory nausea, vomiting, small bowel resection or any other gastrointestinal ailment that would preclude study drug absorption.
  8. Cardiac abnormalities

    • Mean QTc interval ≥ 480 msec at screening.
    • ACS/AMI -within 24 weeks prior to screening.
    • PCI/PTCA -within 24 weeks prior to screening.
    • Symptomatic heart failure - NYHA Class ≥ II symptoms.
  9. Active infection within one-week prior to study, including unexplained fever
  10. Systemic steroid or other immunosuppressive therapy within 4 weeks of starting the study.
  11. Lactating females and/or pregnant females.
  12. Any significant psychiatric disease, medical or other condition, which in the opinion of the principal investigator could prevent adequate informed consent or compromise participation in the clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02818023


Locations
Layout table for location information
United States, Pennsylvania
UPMC Cancer Center Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
Yana Najjar
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Yana M. Najjar, MD University of Pittsburgh
Layout table for additonal information
Responsible Party: Yana Najjar, Principal Investigator, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02818023    
Other Study ID Numbers: 15-131
First Posted: June 29, 2016    Key Record Dates
Last Update Posted: July 14, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Pembrolizumab
Vemurafenib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action